Enzo Biochem (NYSE: ENZ) reported Q2 EPS of $0.09, versus ($0.12) reported last year. Revenue for the quarter came in at $31.5 million, versus $19.4 million reported last year.

• Dr. Elazar Rabbani, Founder and CEO, to step down as CEO and transition to a scientific role with the Company once a qualified successor is identified and hired by the Board
• Executive search firm Korn Ferry engaged to identify CEO candidates
• Gary M. Huff, former LabCorp Diagnostics CEO, named Strategic Consultant to Board
• Enzo retains Cain Brothers to help identify, evaluate, and execute strategic initiatives

For earnings history and earnings-related data on Enzo Biochem (ENZ) click here.